외래 종양학 주입 치료 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Outpatient Oncology Infusion Market was valued at USD 2.9 billion in 2025 and is estimated to grow at a CAGR of 10.6% to reach USD 8 billion by 2035.

The market expansion is fueled by increasing preference for cost-efficient outpatient care, rising cancer prevalence, government initiatives promoting cancer awareness, and advancements in infusion technologies. Rising adoption of targeted therapies and immunotherapies, the shift toward value-based care, and telehealth-assisted infusion services are further driving demand. Lifestyle factors, obesity, and environmental influences contribute to the growing number of cancer cases, increasing the need for effective and accessible treatments. Outpatient infusion centers provide patients with a more convenient and efficient treatment model while reducing overall costs compared to hospitalization. Additionally, the integration of advanced smart infusion pumps with automated dosing, error alerts, and electronic health record (EHR) compatibility has enhanced both safety and operational efficiency, strengthening the appeal of outpatient oncology infusion services worldwide.

The infusion pumps segment held a 50.2% share in 2025. These devices, featuring portable designs and smart system integration, enhance patient comfort, allow flexible administration, and support precise dosing. Technological improvements in pumps are central to the growth of outpatient infusion services.

The targeted therapy segment accounted for a 39.5% share in 2025. These therapies act on specific molecular pathways linked to cancer and delivered through controlled infusion. Outpatient infusion centers are preferred for their administration, driving the need for advanced infusion devices and skilled personnel to monitor accurate dosing and patient response.

North America Outpatient Oncology Infusion Market held 43.1% share in 2025 and is expected to grow significantly. The region benefits from advanced healthcare infrastructure, a high number of cancer patients, and strong adoption of innovative infusion technologies. Comprehensive insurance coverage and the shift toward value-based care allow patients to access outpatient cancer treatments more affordably than in hospital settings. Adoption of smart infusion pumps and integrated EHR systems in outpatient centers enhances patient safety and operational workflow, further boosting market growth.

Key companies operating in the Global Outpatient Oncology Infusion Market include B. Braun, Baxter, Fresenius Kabi, Medtronic, MOOG, IRADIMED, Micrel, NIPRO, Teleflex, Terumo, ICU Medical, Penlon, and Becton, Dickinson and Company. Companies in the Global Outpatient Oncology Infusion Market focus on strategies such as continuous product innovation in smart infusion pumps, integration of digital health platforms, and development of user-friendly, portable devices to improve patient outcomes. Expansion into new geographic regions and partnerships with healthcare providers enhance market reach. Firms also invest in training programs for clinical staff to ensure accurate administration of therapies. Additionally, collaborations with telehealth services, EHR integration, and value-based care initiatives strengthen operational efficiency, patient safety, and long-term adoption, helping companies solidify their market foothold and maintain leadership in a competitive environment.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Application trends
  • 2.2.4 Therapy trends
  • 2.2.5 Mode trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cancer across the globe
    • 3.2.1.2 Increasing preference for cost-effective outpatient care
    • 3.2.1.3 Technological advancements in infusion pumps
    • 3.2.1.4 Surging government initiatives for cancer awareness
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs of cancer therapies
  • 3.2.3 Opportunities
    • 3.2.3.1 Adoption of smart infusion pumps with EHR interoperability
    • 3.2.3.2 Development of biosimilars to reduce treatment costs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 LAMEA
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Value chain analysis
• 3.7 Reimbursement scenario
• 3.8 Policy landscape
• 3.9 Epidemiology scenario
• 3.10 Porter's analysis
• 3.11 PESTEL analysis
• 3.12 Gap analysis
• 3.13 Future market trends

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
  • 4.3.5 LAMEA
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Infusion pumps
• 5.3 Intravenous sets
• 5.4 IV cannulas
• 5.5 Needleless connectors

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Lung cancer
• 6.3 Liver cancer
• 6.4 Breast cancer
• 6.5 Prostate cancer
• 6.6 Other cancers

Chapter 7 Market Estimates and Forecast, By Therapy, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Chemotherapy
• 7.3 Targeted therapy
• 7.4 Immunotherapy
• 7.5 Hormonal therapy

Chapter 8 Market Estimates and Forecast, By Mode, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Intramuscular (IM)
• 8.3 Intravenous (IV)
• 8.4 Subcutaneous
• 8.5 Other modes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 MEA
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Nigeria
  • 9.6.5 Egypt

Chapter 10 Company Profiles

• 10.1 B. Braun
• 10.2 Baxter
• 10.3 Becton, Dickinson and Company
• 10.4 Fresenius Kabi
• 10.5 ICU Medical
• 10.6 IRADIMED
• 10.7 Medtronic
• 10.8 Micrel
• 10.9 MOOG
• 10.10 NIPRO
• 10.11 Penlon
• 10.12 Teleflex
• 10.13 Terumo